RedHill Biopharma (RDHL) Updates on BEKINDA Progress; Will Conduct Additional Data Collection in Phase 3
Tweet Send to a Friend
RedHill Biopharma (NASDAQ: RDHL) provided an update on its development programs with BEKINDA (RHB-102), a proprietary, extended-release, once-daily oral pill ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
